Experimental neurology

Group leader

José Antonio Rodríguez Navarro

jose.a.rodriguez(ELIMINAR)@hrc.es

Tlf.: +34 91 336 9213

Principal Investigators

  • Amelia Sánchez Capelo
  • Ana María Pérez Castillo
  • Luis Carlos Barrio Calvo

Collaborators

  • José Antonio Barios Heredero
  • Daniel González Nieto
  • Gustavo Lorenzo Sanz
  • José Luis Lopez-Sendón Moreno
  • Eulalia Bazán Izquierdo
  • Cristina Medrano Viñas
  • Carlos Luis Paíno Belarrinaga
  • Diana Reimers Cerdá
  • Adriano Jiménez Escrig
  • Guillermo García Ribas
  • Marta del Álamo de Pedro
  • Juan Carlos Martínez Castrillo
  • Araceli Alonso Cánovas
  • Gregorio Ángel Santos Montes
  • José Ángel Morales García
  • Javier Gutiérrez Luengo
  • María José Casarejos Fernández
  • Ana Maria Casarrubios Lazaro
  • Jesus Alarcon Gil
  • Marta Posada Gracia
Imagen equipo

Group leader

José Antonio Rodríguez Navarro

jose.a.rodriguez(ELIMINAR)@hrc.es

Tlf.: +34 91 336 9213

Principal Investigators

  • Amelia Sánchez Capelo
  • Ana María Pérez Castillo
  • Luis Carlos Barrio Calvo

Collaborators

  • José Antonio Barios Heredero
  • Daniel González Nieto
  • Gustavo Lorenzo Sanz
  • José Luis Lopez-Sendón Moreno
  • Eulalia Bazán Izquierdo
  • Cristina Medrano Viñas
  • Carlos Luis Paíno Belarrinaga
  • Diana Reimers Cerdá
  • Adriano Jiménez Escrig
  • Guillermo García Ribas
  • Marta del Álamo de Pedro
  • Juan Carlos Martínez Castrillo
  • Araceli Alonso Cánovas
  • Gregorio Ángel Santos Montes
  • José Ángel Morales García
  • Javier Gutiérrez Luengo
  • María José Casarejos Fernández
  • Ana Maria Casarrubios Lazaro
  • Jesus Alarcon Gil
  • Marta Posada Gracia

STRATEGIC OBJECTIVES

General: Identification of key events or molecules in the pathogenesis of neurological diseases with diagnostic or prognostic significance, or that can likely to be exploited for the development of new therapeutic targets.

Specific

  1. Analyse the role of innate immunity in the control and pathogenic evolution of neurodegenerative diseases.
  2. Study the immunomodulatory, homeostatic and regenerative role of trehalose as an autophagy inductor, as well as the hepatocyte growth factor (HGF) as a potent antioxidant and neurogenerative agent.
  3. Understand the role of the different routes of protein degradation and the metabolic changes in cellular models, animals and patients with neurodegenerative diseases.
  4. Studies of genetic association and metaanalysis to identify new mutations in people with Parkinson's disease. Development of a new genetic diagnosis kit. Clinical trials in patients for new treatments and the early diagnosis of the disease. Preclinical studies in animal models of Parkinson's disease and collaboration with industry to evaluate new therapeutic targets.
  5. Establish the functional basis of neural networks in brain slices as a synaptopathies study model.
  6. Development of synaptogenesis modulatory drugs based on NS1 target.
  7. Characterisation of the Cx36-knockout mouse as a model of sudden infant death syndrome (SIDS) and sleep apnea in adults.
  8. Identification of new mutations in the connexin-47 and connexin-43 genes in patients with leukodystrophia and spastic paraparesis, functional assays of the mutations and the development of a patient-specific model of in vitro myelination by reprogramming.
  9. Study of the impact of a walking exoskeleton on the quality of life of patients with spinal muscular atrophy.

RESEARCH LINES

  • Regulation of neuroinflammation and proteostasis in neurodegenerative diseases.
  • Autophagia in neurodegenerative diseases.
  • Generic studies and clinical trials in Parkinson's disease.
  • Synaptic neurotransmission mechanisms and plasticity in neurological diseases.
  • Development of synaptogenensis modulating drugs.
  • Neurological pathologies associated with connexin channels in neurons, astrocytes and oligodendrocytes.

Location

Neurobiology Service, 1st Floor rigth.
Experimental Neurology Unit, 2nd Floor rigth.
Department of Research.
Ramón y Cajal University Hospital

Keywords

Alzheimer’s, neuroinflammation, neurodegeneration, innate immunity, trehalose, LGF, microglia, Parkinson’s disease, association genetics, clinical trials, TGF-beta, synuclein, early diagnosis, impulse control, dystonias, movement disorders, new therapeutic targets, animal models, neurotransmission, memory mechanisms, epilepsy, connexins, intercellular channels, hemichannels, connexinopathies, sudden infant death syndrome (SIDS), leukodystrophies, spastic paraparesis, cellular reprogramming, myelination, exoskeleton